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Abstract
Background: Bacteremia by Pseudomonas aeruginosa represents one severe infection. It is not clear whether beta-lactam
monotherapy leads to similar rates of treatment success compared to combinations of beta-lactams with aminoglycosides
or quinolones.
Methods: Retrospective cohort study from 3 tertiary hospitals (2 in Greece and 1 in Italy). Pseudomonas aeruginosa isolates
were susceptible to a beta-lactam and an aminoglycoside or a quinolone. Patients received appropriate therapy for at least
48 hours. Primary outcome of interest was treatment success in patients with definitive beta-lactam combination therapy
compared to monotherapy. Secondary outcomes were treatment success keeping the same empirical and definitive
regimen, mortality, and toxicity.
Results: Out of 92 bacteremias there were 54 evaluable episodes for the primary outcome (20 received monotherapy).
Treatment success was higher with combination therapy (85%) compared to beta-lactam monotherapy (65%), however not
statistically significantly [Odds ratio (OR) 3.1; 95% Confidence Interval (CI) 0.69–14.7, p=0.1]. Very long (.2 months)
hospitalisation before bacteremia was the only factor independently associated with treatment success (OR 0.73; 95% CI
0.01–0.95, p=0.046), however this result entailed few episodes. All-cause mortality did not differ significantly between
combination therapy [6/31 (19%)] and monotherapy [8/19 (42%)], p=0.11. Only Charlson comorbidity index was associated
with excess mortality (p=0.03).
Conclusion: Our study, in accordance with previous ones, indicates that the choice between monotherapy and combination
therapy may not affect treatment success significantly. However, our study does not have statistical power to identify small
or moderate differences. A large randomized controlled trial evaluating this issue is justified.
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Introduction
Bacteremia caused by Pseudomonas aeruginosa represents one of
the most severe infections in the hospital setting, especially for
immunocompromised or critically ill patients. Recent studies
report overall mortality in patients with this infection between
20% and 60% and mortality solely attributed to the infection
around 15% [1,2,3,4,5]. An important factor, which complicates
these infections, is multidrug-resistance that is very common
among Pseudomonas aeruginosa strains globally, leaving a small
number of appropriate antimicrobials, which are in vitro, at least,
active against them [4,6,7]. Consequently, a number of studies
have highlighted the possible negative effect of inappropriate
empirical antimicrobial therapy on length of hospital stay and
other unwanted outcomes [8]. In addition, there are reports
indicating that early initiation of appropriate therapy may also
play significant role regarding response to treatment [9,10].
The use of antibiotic combinations represents a common
therapeutic approach against infections with Pseudomonas aeruginosa,
used for decades [11,12,13,14]. The rationale for using antibiotic
combinations lies on their different mechanisms of action, their in
vitro synergy and the wide antimicrobial spectrum that they offer
[6,7,14]. However, the administration of more than one
antimicrobial increases toxicity as well as possible drug interactions
between the antimicrobials and with other medications [15,16]. In
addition, there is further increase in antimicrobial resistance by
increased antimicrobial use [17,18,19,20]. During the last 15 years
several original papers and systematic reviews questioned the
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crobials for various serious bacterial infections in immunocompe-
tent and immunocompromised patients [15,16,21,22,23].
Despite the fact that the benefit from combinations of beta-
lactams with other antimicrobials has been considered equivalent
to beta-lactam monotherapy for many serious infections, it is not
clear whether this is true for Pseudomonas aeruginosa bacteremia
[6,22,23]. Few papers focused exclusively in this issue, especially
regarding definitive therapy, based on susceptibility testing results
[24,25,26]. In this retrospective study we review Pseudomonas
aeruginosa bacteremias in which beta-lactam monotherapy and
combination therapy with an aminoglycoside or a quinolone were
both therapeutic options according to antimicrobial susceptibility
test results. We will assess how the two different therapeutic
choices of the clinicians affected clinical success and other
outcomes.
Methods
Setting, study population
This retrospective cohort study included patients from two
tertiary hospitals in Greece and one in Italy. Specifically, we used
records of patients from ‘‘Henry Dunant’’ Hospital in Athens,
University Hospital of Heraklion in Crete, and from the National
Institute for Infectious Diseases ‘‘L. Spallanzani’’ in Rome. The
study period differed in the three centers mainly due to variability
in the available data included in the medical records of patients
throughout the study. Thus, in ‘‘Henry Dunant’’ hospital patient
records were reviewed from January 2002 until August 2005, in
Italy from January 2001 until August 2005, whereas in Heraklion
from February 2003 until August 2007. However, data collection
took place at the same time in the three centres using a specific
case report form.
Inclusion criteria
First, patients with bacteremia from Pseudomonas aeruginosa were
identified by the electronic databases of the microbiology
laboratories of the hospitals. In some cases the relevant
antibiograms were readily available, whereas in others data had
to be found in patients’ hospital records. The Pseudomonas aeruginosa
isolates should be susceptible to a beta-lactam and an aminogly-
coside or a quinolone (mainly ciprofloxacin) so that comparisons
between patients that received beta-lactam monotherapies and
combination therapies would be meaningful. Another inclusion
criterion was the administration of at least one active beta-lactam,
with or without an aminoglycoside, or quinolone (according to the
antimicrobial susceptibility testing results) for at least 48 hours.
Patients with highly resistant polymyxin-only-susceptible strains,
which were rather common during this period, were excluded
from further analysis. Moreover, all patients should have
symptoms indicative of infection, based primarily on the
definitions of systemic inflammatory response syndrome [27].
Primary bacteremias and catheter-related bloodstream infec-
tions were diagnosed according to definitions Infectious Diseases
Society of America [28]. Multiple episodes of bacteremia in the
same patient were included in the analysis as long as they occurred
more than three weeks apart and the patient did not have any
symptoms, signs, or findings consistent with an infection for at least
a week between the two episodes. Only adult patients were
included in the study.
Data collection
Various baseline characteristics of the patients at the time of the
bacteremia that could affect the outcome of the infection were
collected, recorded and analyzed. Variables included age, gender,
and comorbidities of patients (including solid tumors, hematologic
malignancies, neutropenia, recent chemotherapy, HIV infection,
acute and chronic renal failure, respiratory insufficiency, or
cardiac disorders), duration of hospitalization before the occur-
rence of bacteremia, as well as surgeries, ICU hospitalization, and
existence of central venous catheter prior to the bacteremia. In
addition, the site of initial infection was recorded in secondary
bacteremias.
Charlson comorbidity index (CCI) was calculated for all patients
[29,30]. This index takes into account 19 conditions and
categories of diseases, including congestive heart failure, dementia,
tumors, metastatic disease, AIDS, different degrees of hepatic
disease, moderate to severe renal disease, diabetes, connective
tissue disease and hematological malignancies, to name a few. A
large number of conditions that have been encoded in ICD-9 have
received specific grading according to CCI, which we utilized [31].
Antimicrobial therapy
Both patients that received empirical and definitive antimicro-
bial therapies against Pseudomonas aeruginosa bacteremia were
evaluated. Therapy was considered empirical if it was initiated
no later than 24 hours after the specimen from which the
Pseudomonas aeruginosa strain was isolated and definitive if it was
initiated or continued after the result of the blood culture and the
relevant susceptibility testing was available to the clinicians. When
a patient received appropriate empirical therapy that was not
changed after the susceptibility testing result was available, patient
was evaluated twice, both regarding the empirical and definitive
therapy. Only the first definitive (i.e. based on susceptibility testing)
treatment administered to a patient during an episode of
bacteremia was evaluated for the outcomes of interest and not
any further changes. Monotherapy was considered any therapy
that included only a beta-lactam antibiotic. Combination therapy
included a beta-lactam antibiotic plus either an aminoglycoside or
a quinolone. Patients that had received three or more active
antibiotics (e.g. an aminoglycoside plus ciprofloxacin plus a beta-
lactam) were excluded from the analysis. Similarly, no other
regimen that included agents active against Pseudomonas aeruginosa
(e.g. colistin) was evaluable. All patients included in the study
received commonly used doses of antibiotics for sufficient time, in
concordance with various guidelines [28,32,33,34].
Studied outcomes
The primary outcome of interest was treatment success in
patients that had bacteremia from isolates susceptible to a beta-
lactam and at least one of the two other studied antimicrobial
categories (aminoglycosides or quinolones) and who received
either beta-lactam as monotherapy or in combination with
another active antimicrobial. Treatment was considered successful
if all signs and symptoms of infection due to Pseudomonas aeruginosa
were absent after the end of antimicrobial therapy and remained
so for at least one week. Any blood cultures after the beginning of
therapy and for at least one week after its discontinuation should
also be negative for Pseudomonas aeruginosa. Therapy was considered
as failure if re-isolation of Pseudomonas aeruginosa in blood or other
tissues occurred within a week after the end of therapy, if the
patient had no clinical improvement or had deterioration, or if
death due to infection occurred during therapy.
If therapy was changed due to a superinfection with another
microbe or it was discontinued due to toxicity, the outcome was
evaluated on the basis of the clinical response that the patient had
until the moment the regimen was changed if this was
straightforward (clearly improving or deteriorating), otherwise
Therapy for Pseudomonas aeruginosa Bacteremia
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of interest were: i) treatment success in patients that received the
same empirical and definitive regimen, ii) toxicity caused by the
antimicrobial agent, requiring discontinuation of it or significant
dose adjustment (decrease larger than 1/3 of the original dose, and
iii) infection-related and all-cause mortality.
Microbiological testing
Identification and susceptibility testing of the P. aeruginosa
isolates were performed by using an automated broth microdilu-
tion method (bioMerieux, Vitek II, Hazelwood, MO). The in vitro
susceptibility of the P. aeruginosa blood isolates to amikacin,
gentamicin, netilmicin, tobramycin, ciprofloxacin, pefloxacin,
aztreonam, ticarcillin, ticarcillin/clavulanic acid, piperacillin,
piperacillin/tazobactam, ceftazidime, cefepime, cefpirome, imi-
penem, meropenem, trimethoprim/sulfamethoxazole, colistin,
and other antimicrobials was tested. The breakpoints were those
defined by the Clinical and Laboratory Standards Institute (CLSI)
[35,36].
Statistical analysis
Baseline characteristics of patients that received beta-lactam
monotherapy were compared with those of patients that received
combination therapy. In addition, the same variables were
compared in patients with and without treatment success in order
to identify factors associated with success. The rare instances of
different episodes in the same patient were analyzed together with
the rest of patient-episodes, with the exception of mortality
outcomes. Categorical variables were compared by Fischer’s exact
test and relevant exact odds ratios (ORs) were presented for the
main findings. For continuous variables, we used the Student’s t-
test or the Mann-Whitney test for normally and non-normally
distributed variables, respectively. In bivariable analyses of
exposure (therapy) and outcome, adjustments were made for all
variables (baseline characteristics) that differed significantly
(p,0.05) between the monotherapy versus combination therapy
groups, evaluating for possible treatment modification (interac-
tion). A multivariable logistic regression analysis of risk factors for
treatment success was formed. Variables included were those
related to the outcome of interest in bivariable analyses and those
unevenly distributed among the two study groups at a level of p-
value,0.05. Variables included in the final multivariable model
were further examined to exclude any collinearity among them.
Type of therapy (combination versus monotherapy) is the only
variable that would be included in a separate multivariable
analysis, in case of non-significance in bivariable analyses. All
statistical analyses were performed using Stata 9.2 statistical
software (StataCorp LP, TX, USA).
Results
Ninety-two patient-episodes with Pseudomonas aeruginosa bacter-
emia were identified in the databases of the included hospitals. A
significant proportion of them had multiresistant strains suscepti-
ble only to colistin (17 episodes). In 4 episodes Pseudomonas
aeruginosa was susceptible only to a beta lactam, in 4 episodes
susceptible only to an aminoglycoside or quinolone, 4 episodes
were treated with ciprofloxacin monotherapy, and 1 episode
received 3 antimicrobials from the included classes, thus all these
episodes were excluded. Two patients died within 12 hours from
admission and in 3 other cases important data regarding therapy
and outcome were not included in the medical records. Overall 57
episodes of PA bacteremia (in 53 patients) were treated for
sufficient duration with appropriate empiric therapy (39 episodes),
definitive therapy (54 episodes), or both (36 episodes). All patients
had sepsis, defined by at least two clinical manifestations of SIRS
(fever or hypothermia, tachycardia, tachypnea, and/or abnormal
WBC count).
Primary outcome
There were 54 evaluable episodes in 50 patients for the primary
outcome of interest, i.e. treatment success in episodes of
bacteremia due to isolates susceptible to a beta-lactam and an
aminoglyscoside or a quinolone and were treated either by
monotherapy or combination therapy. Twenty two episodes
occurred in Athens, 17 in Crete, and 15 in Italy. Twenty eight
(52%) were in female patients, with median age 56 (25–87) years
and median duration of hospitalization prior to bacteremia 4.5 (0–
125) days. In Italy all 15 episodes were admitted in an infectious
diseases department whereas in Greece 14 (36%) were hospitalized
in internal medicine department, 7 (18%) in oncology, 8 (21%) in
surgery, 5 (13%) in ICU and the rest in various departments. Ten
out of fifteen (66%) episodes in Italy occurred in HIV positive
patients, since the National Institute for Infectious Diseases in Italy
is a reference centre for HIV.
A total of 20 episodes (37%) received monotherapy and the rest
34 received combination of a beta-lactam with an aminoglycoside
or a quinolone [20 (37%) and 14 (26%) episodes, respectively].
The most commonly used beta-lactam as definitive therapy was
ceftazidime, piperacillin (plus tazobactam), imipenem (plus
cilastatin), and meropenem used in 20 (37%), 15 (28%), 6 (11%),
and 6 (11%) episodes of which in 8, 6, 4, and 1 were administered
as monotherapy, respectively. Amikacin and ciprofloxacin were
the most commonly used aminoglycoside and quinolone, used in
60% and 86% of relevant combinations, respectively. Steroid
therapy, blood products transfusions, and bone marrow-stimulat-
ing factors were used with similar frequencies in the two treatment
groups. In 25 (46%) cases bacteremia was primary whereas a
central venous catheter was the source in another 11% of cases.
Respiratory tract, urinary tract, and abdomen were the source of
infection in 17%, 4%, and 15% of the infections, respectively.
Table 1 shows baseline characteristics of patients that received
monotherapy compared to those that received combination
therapy. As shown, monotherapy was used more often compared
to combination therapy in patients with HIV whereas the opposite
was true for those that had been hospitalized in the ICU prior to
or at the time of the bacteremia. Regarding the Charlson
comorbidity index, a high number of points (six) is assigned to a
patient with HIV. Thus, although high Charlson index was
observed in patients that received monotherapy compared to
combination therapy (5.9 versus 4.1, p=0.02), this difference was
not retained when adjustments for HIV were performed (9.4
versus 7.7, p=0.2 for patients with HIV and 4 versus 3.7, p=0.6
for patients without, data not shown). In another comparison (not
shown), no significant difference was noted regarding the body
source of infection in patients that received monotherapy and
those that received combination therapy. Finally, no significant
difference existed between treatment groups regarding the
presence of organ failure (cardiovascular, respiratory, renal,
hepatic, and bone marrow), as shown in Table 1.
Table 2 shows the characteristics of patients that had a
successful primary outcome compared to those that had treatment
failures. In 42 episodes (77%) treatment was considered successful.
Use of combination therapy was found to be associated with
higher proportions of treatment success in univariable analysis
compared to beta-lactam monotherapy [29/34 (85%) in combi-
nation versus 13/20 (65%) in monotherapy], however this did not
reach statistical significance [odds ratio (OR) 3.1; 95% Confidence
Therapy for Pseudomonas aeruginosa Bacteremia
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that received combination therapy over those that received
monotherapy]. Separate adjustments for all factors presented in
Table 2 did not alter significantly the effect that combination
therapy had on the outcome. Finally, a bivariable analysis showed
no association between the various sites of infection and treatment
success. Sites included respiratory and urinary tract, skin and soft
tissues, intravenous catheters (central veins), intra-abodminal and
other sites.
As shown, the length of hospitalisation before bacteremia did
not have a statistically significant association with treatment
success overall. When a cut-off point of 48 hours of hospitalisation
prior to bacteremia was set, segregating non-hospital from
hospital-acquired infections, again no significant difference in
treatment success was identified (81% versus 76% of community
versus hospital infections, respectively, had a good outcome, data
not shown). On the contrary, the few (n=4) patients with very
long hospitalisations of more than two months had low rates of
treatment success (25% versus 82% for the rest of patients,
p=0.03).
Variables with p,0.05 in bivariate analyses presented in
Tables 1 and 2 as well as type of therapy (combination versus
monotherapy) were included in a logistic regression model
(Table 3). As shown, a very long hospitalisation before bacteremia
was the only factor that had a statistically significant (negative)
association with treatment success in the multivariable model did
not substantially alter the results. Elimination of type of therapy
and HIV (which is included in Charlson’s comorbidity index) did
not substantially alter the results. Similarly, when eliminating long
hospitalization (since it is relevant to only a small proportion of
patients- outliers) treatment success in combination therapy over
monotherapy group was: OR 2.7, 95% CI 0.6–12.1, p-value 0.21.
Overall, no multivariable model predicted the outcome with more
precision than very long hospitalization alone.
Secondary outcomes
A subanalysis was performed for patients that received the same
empirical and definitive regimen, without any change in treatment
after the susceptibility testing results. Appropriate empirical
therapy was administered in 39 cases, however 3 were not
Table 1. Comparison of baseline characteristics and primary outcome in beta-lactam monotherapy and combination therapy
groups.
Definitive therapy Monotherapy, n=20 Combination therapy n=34 p-value
(SE, 95% percentiles, or %)
Age 64.5 (31.5–81) 55 (31–81) 0.94*
Female 8 (40)2 0 ( 59) 0.26
Location: 0.16
- Athens 5 (23) 17 (77)
- Rome 8 (53) 7 (47)
- Heraklion 7 (41) 10 (59)
Days hospitalized prior to bacteremia 3 (0–94) 5 (0–61) 0.47*
Patients with very long hospitalization prior to bacteremia 2 (10) 2 (6) 0.62
Hospitalization in ICU prior to bacteremia 1 (5)1 2 ( 35) 0.02
Bacteremia during ICU stay 1 (5)1 0 ( 29) 0.04
Cardiovascular dysfunction** 2 (10)7 ( 21) 0.46
Renal dysfunction** 6 (30)5 ( 15) 0.29
Respiratory dysfunction** 4 (20)7 ( 21) 1
Hepatic dysfunction** 4 (20)7 ( 20) 1
Hematologic dysfunction** 4 (20)6 ( 18) 1
Solid tumor 8 (40)1 3 ( 38) 1
Neutropenia{ 3( 15)5 ( 15) 1
Recent chemotherapy 4 (20)1 0 ( 30) 0.53
HIV 7 (35)3 ( 8) 0.03
- AIDS 6 (30) 3 (8) 0.06
DM 2 (10)1 0 ( 29) 0.17
Operations prior to isolation 1 (5)8 ( 24) 0.13
Charlson comorbidity index 5.9 (60.8) 4.1 (60.4) 0.02
Age - adjusted Charlson comorbidity index 7.6 (60.6) 5.5 (60.5) 0.01
Primary bacteremia 10 (50)1 5 ( 44) 0.78
Other organism in blood culture 1 (5) 7 (21) 0.23
Days of delay in administration of appropriate therapy 0 (0–4.5) 0 (0–3) 0.93*
*Not normal distribution, median values presented, p-value calculated by Mann-Whitney test.
**Defined as any degree of failure resulting from acute or chronic pathology, not including low CD4.
{Alone or as part of pancytopenia.
doi:10.1371/journal.pone.0026470.t001
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combination therapy was not an option for definitive therapy).
Thus, 36 cases were evaluable both for empirical and definitive
therapy. In 12 cases (33%) initial therapy was changed whereas in
the rest of cases not. No statistically significant difference in
treatment success was noted between the cases in which therapy
was changed (8/12) and those that received the same monother-
apy (4/6) or combination therapy (14/18) throughout the infection
(p=0.7, Fischer’s exact). The group with initial beta-lactam
monotherapy did not differ significantly from combination therapy
regarding overall treatment success (6/11 versus 20/25 episodes,
p=0.22). Baseline characteristics of patients that are reported in
Tables 1 and 2 were also tested for association with appropriate
empirical beta-lactam monotherapy or combination therapy in
these patients. These characteristics did not differ significantly
among the two treatment groups (data not shown).
All-cause mortality did not differ significantly between the two
treatment groups [6/31 (19%) versus 8/19 (42%) patients in
combination versus monotherapy group, p=0.11]. None of the
factors presented in Table 2 were associated with excess mortality
except from CCI and age-adjusted CCI (p=0.05 and 0.03,
respectively). There were 8 deaths due to infection among the 12
Table 2. Comparison of baseline characteristics of patients with and without treatment success.
Outcome Success (n=42) Failure (n=12) p-value
(SE, 95% percentiles, or %)
Age 57 (31–81) 55.5 (32–77) 0.55*
Female 22 (52)6 ( 50) 1
Hospital: 0.55
- Athens 18 4
- Rome 10 5
- Heraklion 14 3
Days hospitalized prior to bacteremia 4.5 (0–57) 4.5 (0–125) 0.52*
Patients with very long hospitalization prior to bacteremia 1 (2) 3 (25) 0.03
Hospitalization in ICU prior to bacteremia 11 (26)2 ( 17) 0.71
Bacteremia during ICU stay 10 (24) 1 (8) 0.42
Cardiovascular dysfunction** 8 (19)1 ( 8) 0.67
Renal dysfunction** 8 (19)3 ( 25) 0.69
Respiratory dysfunction** 7 (17)4 ( 33) 0.24
Hepatic dysfunction** 10 (24)1 ( 8) 0.42
Hematologic dysfunction** 7 (17) 3 (25) 0.67
Solid tumor 15 (36)6 ( 50) 0.50
Neutropenia{ 6( 14)2 ( 17) 1
Recent chemotherapy 10 (24)4 ( 33) 0.49
HIV 6 (14)4 ( 33) 0.20
- AIDS 5 (12) 4 (33) 0.10
DM 10 (24)2 ( 17) 0.71
Operations prior to isolation 8 (19)1 ( 8) 0.67
Charlson comorbidity index 4.5 (60.4) 5.7 (60.8) 0.19
Age - adjusted Charlson comorbidity index 6.1 (60.5) 6.9 (60.7) 0.39
Primary bacteremia 20 (48) 5 (42) 0.76
Other organism in blood culture 7 (17) 1 (8) 0.67
Days of delay in administration of appropriate therapy 0 (0–4)0 ( 0–5) 0.52*
Combination therapy 29 (69)5 ( 42) 0.10
Aminoglycoside combination 17 (40)3 ( 25) 0.5
*Not normal distribution, median values presented, p-value calculated by Mann-Whitney test.
**Defined as any degree of failure resulting from acute or chronic pathology, not including low CD4.
{Alone or as part of pancytopenia.
doi:10.1371/journal.pone.0026470.t002
Table 3. Multivariable analysis of factors possibly associated
with treatment success.
Factor OR
95% Conf.
Interval p-value
Very long (.2 months) hospitalization 0.73 0.01–0.95 0.046
Hospitalization in ICU prior to bacteremia 0.67 0.09–4.78 0.69
Age-adjusted Charlson comorbidity index 1.02 0.76–1.38 0.88
HIV 0.59 0.08–4.23 0.60
Combination therapy 3.30 0.63–17.22 0.15
doi:10.1371/journal.pone.0026470.t003
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infection was 3/31 (10%) versus 5/19 (26%) in combination versus
monotherapy group, p=0.23. Only a very long hospitalization
prior to infection was associated with increased infection-related
mortality (p=0.01).
Toxicity was recorded in 4 of 57 episodes that received therapy
for sufficient time. In 2 of these episodes aminoglycosides were
discontinued from empirical combination therapy due to mild
renal toxicity. In another episode, rash possibly associated with the
use of piperacillin/tazobactam plus ciprofloxacin in the empirical
regimen was treated by intravenous use of antihistaminic drugs
without any modification in the antimicrobial therapy adminis-
tered. Finally. combination of oxacillin added to ceftazidime
monotherapy for concomitant infection with Staphylococcus aureus
resulted in neutropenia and the regimen was changed, however
this event is actually non-evaluable for toxicity since it is
combination of 2 beta-lactams. Thus, only patients that received
combinations of antibiotics had some adverse event, however
overall these were few (3/35 versus 0/21 episodes, p=0.29 by
Fischer’s exact test).
Discussion
The results of our study indicate that it is uncertain whether
there is benefit in using combinations of beta-lactams with other
antibiotics when beta-lactam monotherapy can be administered
for Pseudomonas aeruginosa bacteremia, according to susceptibility
testing results. However, this should be interpreted taking into
account that the small population of our study would offer
sufficient statistical power to identify large differences between the
two treatment groups [37]. Specifically, a minimum of 40%
percent difference could be identified with statistical power of
approximately 80% if alpha (p value) would be 0.05 (e.g. 90%
success for combination versus 50% for monotherapy). Neverthe-
less, such a large difference did not exist in our study, but instead a
20% difference was noted in favor of combination therapy.
Of interest, our study indicates that treatment success is
significantly reduced in patients with very prolonged hospitaliza-
tion prior to isolation of Pseudomonas aeruginosa. Actually, this is a
composite risk factor affected by failure to treat the (acute) reason
of admission, comorbidities, and their interaction. It should be
emphasized that prolonged hospitalization itself differs from
chronic comorbidities, a characteristic which was not found to
be independently associated with the studied outcome in this
study. No significant difference in the primary outcome was noted
when the studied cut-off for prior hospitalization was set to
48 hours. Interestingly, Pseudomonas aeruginosa bacteraemia within
48 hours after admission in its great majority is actually considered
a health-related infection, of patients with recent hospitalisations
and manifests as rapidly progressive sepsis in patients presenting
from the community [38] [39].
Several interesting results have been published regarding the
effect that various therapies have on the outcome of Pseudomonas
aeruginosa bacteremia. First, inappropriate empirical therapy was
associated with higher mortality compared to appropriate empirical
therapy, in a study that reported on 305 Pseudomonas aeruginosa
bacteremias during a six-year period [40]. In the same study,
appropriate empirical antimicrobial treatment was more often with
combinations of antibiotics (P=0.01) [40]. On the contrary, Osih
et al, did not identify any significant association between
appropriate empirical therapy and mortality among 167 episodes
of bacteremia (OR 0.96, 95% C|I 0.31–2.93) but only a 7%
reduction in the mean length of stay in patients with appropriate
empirical therapy. In our study, outcome of patients was not
affected by the choice of initial empirical therapy that was continued
as the same definitive therapy afterwards.
In a study of 100 immunocompetent patients, delayed
appropriate definitive therapy beyond 52 hours after bacteremia
was independently associated with 30-day mortality (OR 4.1; 95%
CI 1.2–13.9, P=0.03) [9]. In our study no such association was
found, however we examined it on a day rather than hour-scale. In
127 episodes in a hematologic unit pneumonia, septic shock,
neutropenia, delayed and inappropriate definitive antibiotic thera-
py, and unresponsive underlying disease had negative impact on
the outcomes [10]. On the other hand, appropriateness of therapy
was not associated with better outcomes in a multicenter study that
analyzed 148 patients [41]. Nevertheless, according to most
reports, in accordance to basic pharmacological principles, one
should take for granted that inappropriate definitive antibiotic
therapy is independently associated with a poor outcome [25,42].
In our study all episodes received appropriate therapy.
Interestingly, no significant difference in the cure rates was
observed with use of definitive beta-lactam monotherapy compared
to combination therapy, in 230 episodes in cancer patients [43].
However, combination therapy was a small proportion of all
episodes with aminoglycoside being administered in 14% of
episodes and ciprofloxacin only in 3%. In addition, the definition
of therapy as appropriate was not based on susceptibility testing
but on the existence of anti-pseudomonal drugs in the initial
regimen. In another study, Siegman-Igra et al analysed 57
episodes, in which definitive monotherapy versus combination
therapy resulted in equal infection-related mortality [25].
Nevertheless, ciprofloxacin monotherapy was also included in
the monotherapy group whereas combination group did not
necessarily include a beta-lactam [25]. In that study finer measures
of outcomes such as treatment success were not reported. Instead,
the authors also reported all-cause mortality, which was lower in
monotherapy versus combination therapy group [7/42 (17%)
versus 7/17 (47%), respectively, p=0.05].
Finally, in a study of 79 evaluable episodes of definitive therapy,
Chamot et al found that compared to adequate definitive
combination therapy, the risk of death at 30 days was higher
with inadequate definitive therapy but not with adequate definitive
monotherapy (adjusted Hazards Ratio 0.70; 95% CI 0.30–1.7)
[24]. Our results are in accordance with the aforementioned
studies regarding definitive therapy, since the difference between
combination therapy and monotherapy did not reach statistical
significance. Notably, we included only beta-lactam monotherapy
cases that, according to the susceptibility testing, could also have
received a combination of antibiotics. On the contrary, in the
above studies it is not clear how many of the appropriately treated
patients in the monotherapy group had isolates that were
susceptible only to beta-lactams (including carbapenems), in
whom the addition of another agent would not be an option
[24,43]. Thus, all episodes presented in our study had equal
chances from a microbiological viewpoint to receive monotherapy
or combination therapy although they were not randomized.
Our study has several limitations. First of all, the study
population was rather small to detect small differences in outcomes
between the two treatment groups [37]. This was mainly due to
the narrow inclusion criteria that were used for the two treatment
groups based on the susceptibility of Pseudomonas aeruginosa isolates.
Second, patients from three different hospitals were included,
which could lead to heterogeneous populations. However, all
patients had infections with isolates of similar susceptibility and
received similar health services. The only actual difference was the
high proportion of HIV seropositive cases in Italy due to the fact
that the hospital is a reference centre for such patients. Of note,
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bivariable nor on multivarible analyses of treatment success.
Previous studies have also shown that this population, although
younger, has comparable outcome with the seronegative popula-
tion with Pseudomonas aeruginosa bacteremia [42]. Third, an index of
severity of illness such as APACHE II would be very useful.
However, due to the retrospective design of our study, relevant
data would probably be missing for some non-ICU patients or
would not be present at the same day of bacteremia. Thus, we
presented data regarding failure of vital organs around the time of
infection and CCI. Finally, a retrospective study can be more
easily subject to forms of bias, especially misclassification of cases.
On the other hand, due to a strict methodology no missing values
existed in our dataset after the completion of patient data
collection.
In conclusion, the results from our study indicate that, in
patients with Pseudomonas aeruginosa bacteremia, the choice between
beta-lactam monotherapy and combination therapy with an
aminoglycoside or quinolone does not affect treatment success
significantly, or if such difference exists it is not large enough to be
identified by the sample size of our study. These results are in
agreement with previous studies, which however elaborated
different methodology. A multicentre, appropriately designed,
randomized study comparing beta-lactam monotherapy with
combination therapy for Pseudomonas aeruginosa bacteremia if
justified.
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